Vyne Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

YARROW BIOSCIENCE

08/08/2025 16:34

Vyne Therapeutics Inc VYNE.OQ VYNE.O is expected to  show a fall in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2025

The Bridgewater New Jersey-based  company is expected to report a 24.2% decrease in revenue to $150 thousand from $198 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Vyne Therapeutics Inc is for a loss of 22 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Vyne Therapeutics Inc is $4.50, about 91.6% above its last closing price of $0.38

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.29
-0.29
-0.20
Beat
31
Dec. 31 2025
-0.30
-0.30
-0.28
Beat
7.7
Sep. 30 2024
-0.23
-0.23
-0.29
Missed
-23.4​
Jun. 30 2024
-0.19
-0.19
-0.22
Missed
-15.8
​​Mar. 31 2024
-0.24
-0.24
-0.15
Beat
37.5
Dec. 31 2023
-0.50
-0.50
-0.20
Beat
60​
Sep. 30 2023
-0.76
-0.76
-2.01
Missed
-164.5
Jun. 30 2023
-1.99
-1.99
-3.09
Missed
-55.3

This summary was machine generated August 8 at 15:34 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)